688026 洁特生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.7264.0306.4803.0308.309
总资产报酬率 ROA (%)1.1982.8074.5552.1536.297
投入资产回报率 ROIC (%)1.2893.0314.8952.3046.918

边际利润分析
销售毛利率 (%)39.40541.39341.41330.62231.842
营业利润率 (%)8.64111.05717.1378.51715.757
息税前利润/营业总收入 (%)17.36514.80019.3609.37114.891
净利润/营业总收入 (%)7.9438.70513.6797.57914.380

收益指标分析
经营活动净收益/利润总额(%)83.993129.381107.722112.525102.048
价值变动净收益/利润总额(%)7.3493.971-1.048-2.077-1.706
营业外收支净额/利润总额(%)0.158-2.343-0.123-2.9321.954

偿债能力分析
流动比率 (X)7.7537.5256.6837.4567.022
速动比率 (X)6.1766.2845.5956.6395.989
资产负债率 (%)30.28329.64230.09228.81028.979
带息债务/全部投入资本 (%)23.82323.45222.52122.56521.436
股东权益/带息债务 (%)312.202319.544335.244335.003357.004
股东权益/负债合计 (%)227.850235.640230.889246.970244.923
利息保障倍数 (X)1.9943.7048.6258.550-12.625

营运能力分析
应收账款周转天数 (天)84.846103.615101.81990.36872.624
存货周转天数 (天)157.696143.409117.855117.256107.369